What is Boulder Biologics?
Boulder Biologics operates at the intersection of advanced integrative and regenerative medicine, providing specialized treatments such as stem cell therapy, platelet-rich plasma (PRP), and prolotherapy. The organization distinguishes itself through a focus on autologous biologic therapies designed to facilitate tissue repair and functional recovery for orthopedic patients. Beyond musculoskeletal health, the clinic has expanded its mandate to include longevity medicine, targeting complex health challenges such as metabolic syndrome and age-related decline. By maintaining strict adherence to FDA guidelines, the company ensures that its patient-centered care model remains both safe and clinically effective, establishing a strong market presence in the high-growth field of personalized biological interventions.
How much funding has Boulder Biologics raised?
Boulder Biologics has raised a total of $50K across 1 funding round:
Debt
$50K
Debt (2021): $50K with participation from PPP
Key Investors in Boulder Biologics
PPP
Public-Private Partnership
What's next for Boulder Biologics?
With the recent infusion of capital, Boulder Biologics is poised to accelerate its strategic growth initiatives. The company is expected to prioritize the expansion of its clinical footprint and the enhancement of its research capabilities in autologous therapies. As the firm transitions through its current Series B/C stage, the focus will likely shift toward optimizing operational efficiencies and scaling its longevity medicine offerings to meet rising consumer demand. This financial backing provides the necessary runway to solidify its leadership in the regenerative healthcare space while continuing to pioneer evidence-based treatments for tissue regeneration and metabolic health.
See full Boulder Biologics company page
